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Genome-wide association studies have identiﬁed novel risk variants for Alzheimer’s disease (AD). Among
these, a gene carrying one of the highest risks for AD is PICALM. The PICALM rs3851179 A allele is thought
to have a protective effect, whereas the G allele appears to confer risk for AD. The inﬂuence of the PICALM
genotype on brain function in nondemented subjects remains largely unknown. We examined the
possible effect of the PICALM rs3851179 genotype on quantitative electroencephalography recording at
rest in 137 nondemented volunteers (age range: 20e79 years) subdivided into cohorts of those younger
than and those older than 50 years of age. The homozygous presence of the AD risk variant PICALM GG
was associated with an increase in beta relative power, with the effect being more pronounced in the
older cohort. Beta power elevation in resting-state electroencephalography has previously been linked to
cortical disinhibition and hyperexcitability. The increase in beta relative power in the carriers of the AD
risk PICALM GG genotype suggests changes in the cortical excitatory-inhibitory balance, which are
heightened during normal aging.
 2016 Elsevier Inc. All rights reserved.1. Introduction
Genetic predisposition and increasing age are the greatest
known risk factors for AD. Mutations of the APP, presenilin-1
(PSEN1), and presenilin-2 (PSEN2) genes are causative factors for
early onset AD (Goate et al., 1991; Levy-Lahad et al., 1995; Rogaev
et al., 1995; Sherrington et al., 1995). Polymorphisms of the apoli-
poprotein E (ApoE) gene are the most prevalent genetic risk factors
for late onset AD in Caucasian ethnic groups, including the Russian
population (Farrer et al., 1997; Rogaev, 1999; Saunders et al., 1993;
Schmechel et al., 1993). Recent genome-wide association studies
have identiﬁed novel risk variants for AD (Benitez et al., 2014;
Chauhan et al., 2015; Harold et al., 2009; Lambert et al., 2009;
Liu et al., 2013; Naj et al., 2014). The putative epistatic interactionrtment, Research Center of
64, Russia. Tel.: þ7(495)917-
A 01604, USA. Tel.: þ1 (774)
nomareva), Evgeny.Rogaev@
ll rights reserved.of the novel risk variants with the APOE ε4 variant in the risk for AD
has been demonstrated (Golenkina et al., 2010; Naj et al., 2014).
Among the identiﬁed genes, phosphatidylinositol clathrin assembly
lymphoid-myeloid leukemia (PICALM, chrm 11q14) is currently one
of the top 6 risk genes for AD in the AlzGene database (http://www.
AlzGene.org).
Understanding how the genes identiﬁed in association studies
inﬂuence AD pathogenesis can potentially contribute to the earlier
prediction of AD and the use of personalized prevention strategies
in individuals at risk for AD.
The PICALM protein has been implicated in clathrin-mediated
endocytosis (Ford et al., 2001). Clathrin-mediated endocytosis is
responsible for the internalization of receptors, the recycling of
membrane components, and the regulation of autophagic processes
(Xu et al., 2015). Convincing data indicate that genetically directed
changes in PICALM function lead to alterations in APP processing
through endocytic pathways, amyloid beta (Ab) production (Xiao
et al., 2012) and Ab clearance into the bloodstream (Ando et al.,
2013; Baig et al., 2010; Parikh et al., 2014). PICALM may also
contribute to AD development due to defects in autophagy and the
clearance of tau, which is an autophagy substrate (Moreau et al.,
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and is abnormally cleaved in Alzheimer’s brains (Ando et al., 2013).
PICALM may cause synaptic perturbations by modulating the
abundance of the glutamate receptor subunit GluR2 (Harel et al.,
2011; Harold et al., 2009) and may inﬂuence AD risk by disrupt-
ing iron homeostasis and lipid metabolism (Xu et al., 2015).
The inﬂuence of the PICALM genotype on hippocampal volume
and the thickness of the entorhinal cortex was found in patients
with AD and mild cognitive impairment (MCI), and in normal
controls (Bifﬁ et al., 2010). Gene-wide scoring highlighted PICALM
as the most signiﬁcant gene associated with entorhinal cortical
thickness (Furney et al., 2011).
However, the mechanism by which PICALM polymorphisms in-
ﬂuence brain function in nondemented subjects remain largely
unknown. The SNP rs3851179, which was the ﬁrst PICALM SNP
associated with AD risk (Harold et al., 2009), is located in a non-
coding regionw80 kb 50 of PICALM. There are several PICALM SNPs
(e.g., rs543293, rs659023, rs7110631, rs7941541, and rs3851179) in
linkage disequilibrium with each other and associated with AD
(Harold et al., 2009; Raj et al., 2012; Xu et al., 2016). Hence, the
variant rs3851179 investigated in the present study is tagging the
AD-associated haplotype.
Electroencephalography (EEG) is a powerful and cost-effective
method for studying alterations in brain function during normal
and pathological aging. EEG reﬂects the integrated synaptic activity
of large populations of neurons, which progressively deteriorates in
normal and physiological aging (Buzsaki, 2006). Recent data
showed that EEG may be a valuable biomarker of the development
of the pathologic processes in AD (Babiloni et al., 2006a; Jeong et al.,
2004; Prichep et al., 2006; Moretti et al., 2012). Such biomarkers
can be helpful to estimate the effect of potential therapies to pre-
vent or delay the onset of neurodegenerative diseases (Illarioshkin
et al., 2004; Masdeu et al., 2012).
The primary EEG abnormalities in AD patients consist of a shift
of the power spectrum to lower frequencies and a decrease in the
coherence of fast rhythms (Jelic et al., 1997; Jeong, 2004). AD pa-
tients exhibit a slowing of the dominant EEG frequency, increased
delta and theta power, and decreased alpha power compared to
healthy age-matched controls (Babiloni et al., 2014; Rossini et al.,
2007, van Straaten et al., 2014). MCI, which is in most cases a
prodromal stage of AD, has EEG characteristics intermediate of
those of normal subjects and AD patients (Babiloni et al., 2006a).
Longitudinal studies have revealed EEG-based predictors of future
decline in MCI patients and even in healthy elderly subjects
(Babiloni et al., 2014; Prichep et al., 2006; Van der Hiele et al.,
2008).
Healthy aging is associated with an amplitude decrease in the
posterior alpha rhythm, with the anteriorization of the alpha ac-
tivity and the slowing of alpha frequency (Babiloni et al., 2006b;
Klimesch, 1999; Ponomareva et al., 2013; Tsuno et al., 2002; Volf
and Gluhih, 2011). Several, but not all, studies also reported a
decrease in delta activity and an increase in beta activity during
physiological aging (Babiloni et al., 2006b; Vlahou et al., 2014).
EEG patterns have been suggested as promising tools to assess
endophenotypesdbasic heritable quantitative biological traits thatTable 1
Demographic characteristics of participants
Variable Younger cohort age range (20e50) Olde
PICALM AA and AG PICALM GG PICAL
N 50 23 39
Age (y) 34.4  1.4 37.3  2.3 63.6
Sex (men/women; men%) 18/32; 36% 8/15; 34.8% 14/2
The data are presented as the means and standard errors.more directly reﬂect the inﬂuence of speciﬁc genetic abnormalities
than a complex disorder. Resting-state EEG characteristics are
among the most heritable traits in humans, and the heritability of
the spectral power of different EEG bands is in the range 70%e90%
(van Beijsterveldt et al., 1996). EEG endophenotypes might help to
clarify the role of genetic variants in brain function and disease
development (De Geus, 2010).
Recent studies have demonstrated an association between EEG
characteristics and AD risk variants in the ApoE and CLU genes in AD
and MCI patients and even in healthy adults (Babiloni et al., 2006a;
Jelic et al., 1997; Lee et al., 2012; Lehtovirta et al., 2000; Ponomareva
et al., 2008, 2012, 2013; Stam et al., 2003).
The effect of the PICALM genotype on EEG characteristics has not
been previously investigated.
The present study aimed to determine whether the PICALM
genotype inﬂuences EEG characteristics in nondemented adults,
and to estimate whether this possible effect is modiﬁed over the
course of aging.2. Materials and methods
2.1. Participants
The enrolled cohort included 137 nondemented individuals (47
men and 90 women; age range: 20e79 years).
The subjects were of Russian descent from Moscow and the
Moscow region. The participants underwent a neurologic exami-
nation and cognitive screening. The recruited subjects were free of
dementia and other medical, psychiatric, and neurologic condi-
tions. The exclusion criteria included a history of neurologic and
psychiatric diseases, any type of memory impairment, signs of
clinical depression or anxiety, physical brain injury or other medical
conditions (e.g., hypertension, diabetes, cardiac disease, or thyroid
disease), or a personal history of drug or alcohol addiction.
The Spielberger State-Trait Anxiety Inventory (Spielberger et al.,
1983) and the Hamilton Rating Scale for Depression (Hamilton,
1960) were used to examine anxiety and depression. The subjects
were evaluated with the mini-mental state examination and Clin-
ical Dementia Rating scale (Hughes et al., 1982). Only subjects with
mini-mental state examination scores of 28 or more and Clinical
Dementia Rating scores of 0 were included in the study. All subjects
were right-handed.
Written informed consent was obtained from all the partici-
pants. The experimental protocol for this study was approved by
the local ethics committee. ApoE genotyping was performed for all
participants, and the effect of the ApoE genotype on the EEG char-
acteristics was statistically controlled.
All subjects were divided into subgroups according to the PIC-
ALM (PICALM AA and AG and PICALM GG) polymorphisms. The
PICALM AA and AG group included subjects with the homozygous
PICALM AA or heterozygous PICALM AG genotypes. The PICALM GG
group consisted of subjects with the homozygous PICALM GG ge-
notype. Each group was further subdivided into cohorts of those
younger than and those older than 50 years of age (Table 1).r cohort age range (51e79) All participants age range (20e79)
M AA and AG PICALM GG PICALM AA and AG PICALM GG
25 89 48
 1.3 60.6  1.3 47.2  1.8 49.4  2.1
5; 35.9% 7/18; 28% 32/57; 36% 15/33; 31.3%
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The registration and evaluation of EEG was carried out in
accordance with International Pharmaco-EEG Society guidelines
(Jobert et al., 2013; Versavel et al., 1995). All recordings were ob-
tained in the afternoon from 3 to 4 PM. EEGs were recorded for
3 minutes during the resting state, with the subjects sitting
comfortably in a chair. They were asked to close their eyes and
relax, but to stay awake during the recording. To maintain a con-
stant level of vigilance, an experimenter monitored the subject, and
the EEG traces on-line and verbally alerted the subject any time
when there were signs of behavioral and/or EEG drowsiness.
The EEGs were recorded on Nihon Kohden 4217G EEG (Japan)
using a time constant of 0.3 seconds. The high frequency cutoff was
45 Hz. The 14 Ag/AgCl electrodes were placed according to the in-
ternational 10e20 system at the O2, O1, P4, P3, C4, C3, F4, F3, Fp2,
Fp1, T4, T3, F8, and F7 positions. Linked ears served as the reference.
The electrode impedance did not exceed 10 kU. During the re-
cordings, 180 seconds of EEG at rest was simultaneously sampled at
256 Hz per channel and stored on a computer for further analysis
ofﬂine. The EEG was reviewed visually for artifacts, which were
eliminated from the subsequent analysis. After the artifacts were
eliminated, segments of the resting EEG of 120 seconds in duration
were selected for further analysis.
2.3. EEG analysis
Frequencies below 2 Hz and above 35 Hz were eliminated using
digital ﬁltering. Thirty 4-s artifact-free resting EEG epochs were
processed using fast Fourier transform. The relative powers (% of
the total EEG power) of the delta (2.00e3.99 Hz), theta (4.00e7.99),
alpha (8.00e12.99), beta 1 (13.00e19.99), and beta 2 (20.00e30.00)
bands and the occipital (O2, O1), parietal (P4, P3), central (C4, C3),
frontal 1 (F4, F3), frontal 2 (Fp2, Fp1), mid-temporal 2 (T4, T3), and
anterior temporal (F8, F7) regions were calculated. Log trans-
formations of the relative power of the various bandwidths in each
derivation were calculated to compensate for data skewedness,
according to the recommendations of John et al. (1980), using the
formula log (x/[1  x]), where x is the fraction of total power for
each 4-s sample. The average log relative power for each frequency
band was then calculated. The details of the spectral analysis pro-
cedures have been previously described (Ponomareva et al., 2008,
2012, 2014).
2.4. Genetic analysis
Genomic DNA was isolated from peripheral venous blood using
the standard phenol-chloroform extraction method or a Qiagen
DNA isolation kit. Genotyping was performed using polymeraseFig. 1. Gel electrophoresis of the PICALM gene restriction products. M is the SibEnzyme 100-b
a negative control. Samples 3, 5, 6, 8, 11, 14, and 16 are GG homozygotes; samples 1, 9, 10, 12, a
of the G allele, when SspI cannot digest the PCR product, one 480-bp band is visible. Otherw
Abbreviation: PCR, polymerase chain reaction.chain reaction (PCR), followed by restriction fragment length
polymorphism analysis. Ampliﬁcation was performed according to
the manufacturer’s instructions using both the Tercyc DNA ampli-
ﬁer (DNA technology, Russia) and the GeneAmp PCR System 9700
Thermal Cycler (Applied Biosystems).
The restriction fragment length polymorphism analysis was
developed to genotype the rs3851179 polymorphism of PICALM. We
designed oligonucleotide primers ﬂanking the polymorphic region
of the PICALM gene that contains the rs3851179 polymorphism
primers: PICALM F sequence 50/30 CTCCTTCAACAGCTGCTCCT and
PICALM-R sequence 50/30 TGCTACCCATGTCATCCTCA.
PCR was performed using the Isogen “Core” kits according to the
manufacturer’s instructions. Each assay contained 0.2 mM of each
primer and 30e100 ng of genomic DNA and was run on a GeneAmp
PCR System 9700 Thermal Cycler (Applied Biosystems). The PCR
reaction conditions were as follows: primary denaturation at 95 C
for 1 minute, 35 cycles of denaturation at 95 C for 30 seconds,
annealing at 57 C for 45 seconds, and extension at 72 C for
1 minute, followed by a terminal extension at 72 C for 10 minutes.
The PCR product was digested using the SspI restriction enzyme
(SibEnzyme) at 37 S overnight. The resulting restriction fragments
were analyzed using electrophoresis with 2% agarose gels (Fig. 1).
For the G allele, when SspI cannot digest the PCR product, we
identiﬁed one 480 bp band. Otherwise, the SspI restriction enzyme
digests the PCR product and generates 2 bands, 392 bp and 88 bp,
and this is the A allele.
ApoE genotyping was performed according to previously
described methods (Golenkina et al., 2010).2.5. Statistical analysis
Differences in the demographic and neuropsychological scores
between the groups (PICALM AA and AG young, PICALM GG young,
PICALM AA and AG old, and PICALM GG old) were compared using
an analysis of variance (ANOVA) in the case of the normally
distributed continuous variables (age and education), and the
Mann-Whitney U test for the categorical variables (sex).
The EEG parameters from each group were tested for normal
distribution using the Shapiro-Wilk test, and in none of the cases
were the data found to be skewed.
The signiﬁcance of the differences between the log-transformed
EEG parameters was estimated using repeated measures of ANOVA
in the general linear model (GLM) with genotype (PICALM AA and
AG vs. PICALM GG) and age cohort (old vs. young) as the between-
subject factors, and bands as a within-subject factor. Gender and
ApoE genotypewere included as ﬁxed factors. Post hoc comparisons
for between-subject effects and within-subject effects were
analyzed using the Duncan test, and the level of signiﬁcancewas set
to p < 0.05 for the post hoc comparisons.p marker. C is the uncleaved PCR product, which is equivalent to the G allele and used as
nd 15 are AG heterozygotes; and samples 2, 4, 7, and 13 are AA homozygotes. In the case
ise, SspI digests the PCR product to 2 bands, 392 bp and 88 bp, and this is the A allele.
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genotypes into a single group because the group with the PICALM
AA genotype was relatively small (22 subjects) and because the
control ANOVA analysis with genotype (PICALM AA vs. PICALM AG)
as the between-subject factor did not show signiﬁcant differences
in EEG parameters between the PICALM AA and PICALM AG groups.
3. Results
Table 1 shows the demographic information for the participants.
There were no differences in age and sex between the PICALM GG
and PICALM AA and AG subgroups in either the young or the old
subgroups, or in the whole sample (p > 0.05). There were no sig-
niﬁcant differences in sex between the young and the old sub-
groups with the same PICALM genotype.
Statistical examination of the normalized EEG relative power
values yielded a signiﬁcant main effect for the PICALM genotype
[F(1,131) ¼ 4.09, p ¼ 0.045]. Post hoc comparisons revealed that in
the entire sample, the beta 1 and beta 2 relative power in the
subjects with a homozygous PICALM GG genotype was higher than
that in the subjects with the PICALM AA and AG genotypes
(p ¼ 0.039 for beta 1 and p ¼ 0.033 for beta 2; Fig. 2).
Histograms of the distribution of the values of the beta 1 and
beta 2 relative power in the carriers of the different PICALM geno-
types are presented in Fig. A (Supplementary Materials). The data
conﬁrmed higher values of beta 1 and beta 2 relative power in the
subjects with the PICALM GG genotype than in the individuals with
the PICALM AA and AG genotypes despite othe overlap among the
groups.
Moreover, the distribution of these EEG parameters in the 3
genotype groups (PICALM AA, PICALM AG, and PICALM GG) indicated
that the PICALM AA homozygotes had the lowest beta 1 and beta 2
relative power compared to the non-PICALM AA carriers (Fig. B.
Supplementary Materials). However, the number of PICALM AA
homozygotes was insufﬁcient for an ANOVA to examine differences
of the EEG parameters in the 3 genotype groups.
Fig. C (Supplementary Materials) shows examples of the EEGs in
the subjects with the different PICALM genotypes. A marked in-
crease in beta activity was revealed in the carriers of the PICALM GG
genotype.
The ANOVA revealed a signiﬁcant interaction between the fac-
tors age and EEG bands [F(4,496) ¼ 3.48, p ¼ 0.008] in the whole
sample. Post hoc comparisons demonstrated signiﬁcant differencesFig. 2. Log-transformed relative power (mean and standard error) of the EEG bands in
the subjects with the PICALM GG and PICALM AA and AG genotypes. *p < 0.05; signif-
icant difference between the PICALM GG and PICALM AA and AG carriers. Abbreviations:
EEG, electroencephalography; LnRelP, Log-transformed relative power.in the delta and beta 1 relative power between the older and the
younger subjects. In the older subjects, the log-transformed delta
relative power was 2.24  0.07, whereas in the younger in-
dividuals, this parameter was signiﬁcantly higher (2.05  0.06,
p ¼ 0.045). The log-transformed beta power in the older cohort
was 1.80  0.05, whereas in the younger cohort it was signiﬁ-
cantly lower (2.05  0.05, p ¼ 0.01).
Post hoc comparisons showed that in the subjects with the
PICALM GG genotype, the beta 1 and beta 2 power was signiﬁcantly
higher in the older cohort compared to the younger cohort (p ¼
0.035 for beta 1 and p¼ 0.046 for beta 2). In the older carriers of the
PICALM GG genotype, beta 2 relative power was increased
compared to the older carriers of the PICALM AA and AG genotypes
(Fig. 3).4. Discussion
This study shows that the PICALM rs3851179 polymorphism is
associated with beta relative power in the resting-state EEG of
nondemented adults. An increase in beta 1 and beta 2 relative po-
wer was observed in the carriers of the homozygous AD risk variant
PICALM GG compared to the carriers of the protective PICALM A
allele (PICALM AA and AG genotypes).
This study also showed that the main effect of age was signiﬁ-
cant for the relative power in the delta and beta 1 frequency bands.
Delta power was decreased, and beta power was increased in the
older compared to the younger cohort. This age-related decrease in
delta relative power is consistent with the results of previous
studies (Babiloni et al., 2006b; Leirer et al., 2011; Vlahou et al.,
2014). An increase of beta relative power during aging was previ-
ously found in many (Rossiter et al., 2014; Vlahou et al., 2014;
Vysata et al., 2012), but not all, studies (Babiloni et al., 2006b).
Our results showed that the increase in relative beta power
during aging was signiﬁcant only in the PICALM GG genotype car-
riers; however, similar tendency was observed in all groups. The
genetic heterogeneity of the samples may have caused the dis-
crepancies in the results of previous studies. Accounting for genetic
factors may improve the homogeneity of the results of future
studies in this area.
The beta rhythm is one of the essential functional features of the
brain. This rhythm has been associated with the coordination
among many parts of the neocortex and the mediation of signals
transmitted from higher-order structures to the lower-order
structures (Siegel et al., 2012). Beta oscillations have been re-
ported to be involved in regulating attention, motor planning and
control, multisensory integration, and language processing (Donner
et al., 2009; Leocani et al., 1997, Siegel et al., 2012; Spitzer and
Blankenburg, 2011; Tallon-Baudry et al., 2004; von Stein et al.,
1999).
The beta rhythm is generated in cortico-cortical, cortico-
hippocampal, and cortico-basal ganglia-thalamo-cortical networks
(Cannon et al., 2014, for review). Beta oscillations within these
networks are dependent on the balance between excitatory gluta-
matergic pyramidal cells and inhibitory interneurons, with
GABAergic cells playing the role of pacemakers (Bibbig et al., 2002;
Yamawaki et al., 2008). A signiﬁcant genetic linkage has been found
for the beta frequency in resting EEG with a cluster of GABAA re-
ceptor genes on chromosome 4 (Porjesz et al., 2002).
The increase in beta relative power in the resting-state EEG can
be interpreted as a sign of hyperarousal, central nervous system
disinhibition, and/or hyperexcitability (Enoch et al., 2008;
Fernandez-Mendoza et al., 2016; Jaworska et al., 2012; Riemann
et al., 2010). Elevated beta power was found to be associated with
alterations of inhibitory controls, insomnia, or anxiety (Porjesz and
Fig. 3. Log-transformed relative power (mean and standard error) of the EEG bands in the nondemented younger and older subjects with the PICALM GG and PICALM AG and GG
genotypes. *p < 0.05; signiﬁcant difference between the older versus the younger subjects; þp < 0.05; signiﬁcant difference between the PICALM GG versus the PICALM AA and AG
subjects. Other abbreviations as in Fig. 1.
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Porjesz, 2014; Riemann et al., 2010; Saletu-Zyhlarz et al., 2004).
The association of the PICALM GG genotype with neurophysio-
logical signs of hyperexcitability or disinhibition implies that carrier
of this genotype may be prone to stress reactions. Previous studies
have reported that long-standing distress in midlife increases the
risk of AD (Johansson et al., 2014; Landﬁeld et al., 2007; Lupien
et al., 2007; Sousa et al., 2000).
Given that PICALM GG was reported to have genetics associated
with the risk for AD, the observed GG-associated neurophysiolog-
ical alterations may have a potentially causative contribution to an
increased risk for AD, or alternatively, may be associated with the
early physiological changes that occur decades before AD symp-
toms. Previous research has revealed the inﬂuence of the PICALM
rs3851179 genotype on PICALM expression (Parikh et al., 2014).
Because the PICALM protein modulates glutamatergic synaptic
transmission (Harel et al., 2011) and glutamatergic mechanisms are
essential for beta rhythm generation, it is possible that the EEG beta
alterations found in the carriers of the PICALM GG genotype are
mediated by the changes in glutamatergic neurotransmission.
The neurophysiological signs of hyperexcitability and/or cortical
disinhibition in the PICALM GG carriers revealed in the present
study may be related to the accumulation of pathogenic Ab as-
semblies many years before the manifestation of AD (Ando et al.,
2013; Baig et al., 2010; Parikh et al., 2014), which may elicit aber-
rant excitatory network activity and epileptiform discharges that
could lead to network disinhibition (LaFerla, 1995; Palop and
Mucke, 2009). Tau accumulation in the carriers of the PICALM GG
genotype may also contribute to neuronal hyperexcitability (DeVos
et al., 2013; Moreau et al., 2014). These processes may be related to
the early signs of degeneration in the hippocampus and entorhinalcortex in nondemented adults that have been associated with the
PICALM SNP rs3851179 (Bifﬁ et al., 2010). Further studies are needed
to verify these hypotheses.
EEG alterations in the carriers of the PICALM GG genotype differ
from those in the ApoE ε4 allele carriers; however, both of these
genetic risk variants underlie cerebral disinhibition and/or hyper-
excitability. In a previous study, we found that the presence of the
ApoE ε4 allele in cognitively normal younger adults was associated
with neurophysiological signs of hyperexcitability, which was
characterized by the manifestation of synchronous high-voltage
delta and theta activity and sharp waves under hyperventilation.
It was suggested that aberrant network hyperactivity contributes to
cognitive decline through changes in the expression of neuronal
gene products and the remodeling of neuronal circuits (Palop and
Mucke, 2010; Sanchez et al., 2012) (Bakker et al., 2015). Promising
results have been obtained in recent studies demonstrating that the
use of low doses of antiepileptic drugs can rescue neurophysio-
logical alterations and cognitive deﬁcits in mouse models of AD
(Sanchez et al., 2012), and in patients with amnestic MCI (Bakker
et al., 2015).
In conclusion, this study found an increase in beta relative po-
wer associated with the AD risk PICALM GG genotype in non-
demented adults, with the effect being more pronounced in
subjects older than 50 years. This increase suggests cortical disin-
hibition and/or neuronal hyperexcitability in the carriers of the AD
risk PICALM GG genotype, which is heightened during normal aging.Disclosure statement
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